GAMMA Investing’s ACELYRIN SLRN Stock Holding History

GAMMA Investing’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-678	Closed	-$4.58K	–	3504
2024 Q1	$4.58K	Buy	678 +504	+290%	+$3.83K	﹤0.01%	2448
2023 Q4	$1.33K	Buy	+174	New	+$1.49K	﹤0.01%	2709

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

GAMMA Investing's SLRN Position: Q2 2024 in Review

GAMMA Investing sold out of ACELYRIN (SLRN) in Q2 2024, closing a stake of 678 shares — an estimated $4.58K sold.

GAMMA Investing first reported a position in SLRN in Q4 2023 and held it in 2 quarters. The position peaked at $4.58K in Q1 2024. 112 funds tracked by Wall St. Rank hold SLRN as of Q2 2024.

GAMMA Investing reported no remaining ACELYRIN position as of Q2 2024 after selling out during the quarter.
GAMMA Investing sold 678 ACELYRIN shares in Q2 2024, an estimated $4.58K.
GAMMA Investing first reported a position in ACELYRIN in Q4 2023 and held it in 2 quarters.
GAMMA Investing's ACELYRIN position peaked at $4.58K in Q1 2024.
112 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2024.

Based on GAMMA Investing's 13F filing for Q2 2024, filed 2 Jul 2024.